Senju Pharmaceutical Co., Ltd.
Quick facts
Marketed products
Phase 3 pipeline
- SJP-0035 0.001% · Ophthalmology
SJP-0035 is a topical ophthalmic solution used to treat dry eye disease. - SJP-0132 · Diabetes
SJP-0132 is a small molecule that targets the SGLT2 receptor.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: